MedTrace Logo

CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)

NCT04116047 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 785

Last updated 2026-05-07

No results posted yet for this study

Summary

CompARE is a multicentre, phase III open-label randomised controlled trial using an adaptive, Multi-Arm, Multi-Stage (MAMS) design.

Conditions

  • Oropharyngeal Cancer

Interventions

DRUG

Cisplatin

DRUG

Durvalumab

PROCEDURE

Radiotherapy

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Cancer Trials Ireland

    collaborator NETWORK

  • University of Birmingham

    lead OTHER

Principal Investigators

  • Prof Mehanna · University of Birmingham

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2026-12-31
Completion
2030-12-31

Countries

  • Ireland
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04116047 on ClinicalTrials.gov